

THE CANADIAN JOURNAL OF

# Neurological Sciences

LE JOURNAL CANADIEN DES

# Sciences Neurologiques

AN INTERNATIONAL JOURNAL / UN JOURNAL INTERNATIONAL

## EDITORIAL

- 179 t-PA: A Cause for Tentative Celebration  
*AM Hakim*

## REVIEW ARTICLE

- 181 Neurofibromatosis Type 1: Piecing the Puzzle Together  
*Matthias M. Feldkamp, David H. Gutmann and Abhijit Guha*

## EXPEDITED PUBLICATION

- 192 Identification of six novel SOD1 Gene Mutations in Familial Amyotrophic Lateral Sclerosis  
*Y Boukaftane, J Khoris, B Moulard, F Salachas, V Meininger, A Malafosse, W Camu and GA Rouleau*

## ORIGINAL ARTICLES

- 197 Long-term Glioblastoma Multiforme Survivors: a Population-based Study  
*JN Scott, NB Rewcastle, PMA Brasher, D Fulton, NA Hagen, JA MacKinnon, G Sutherland, JG Cairncross and P Forsyth*
- 202 Unusual Aneurysms of the Distal Internal Carotid Artery  
*Gary J Redkop and Barrie Woodhurst*
- 209 Causes of Morbidity and Mortality Following Intracranial Aneurysm Rupture  
*J Max Findlay and Gail M Deagle*
- 216 Canadian Collaborative Project on Genetic Susceptibility to MS, Phase 2: Rationale and Method  
*AD Sadovnick, NJ Risch, GC Ebers and the Canadian Collaborative Study Group*
- 222 Cost Analysis of Methylprednisolone Treatment of Multiple Sclerosis Patients  
*Lynda S Robson, Charlene Bain, Shann Beck, Suzanne Guthrie, Peter C Coyte and Paul O'Connor*
- 230 Hospital-based Psychiatric Service Utilization and Morbidity in Multiple Sclerosis  
*John D Fisk, Susan A Morehouse, Murray G Brown, Chris Skedgel and T Jock Murray*
- 236 Respiratory Muscle Training in Patients with Moderate to Severe Myasthenia Gravis  
*Patiel Weiner, Ditza Gross, Zeev Meiner, Rushrash Ganem, Margalit Weiner, Doron Zamir and Marinella Rabner*
- 242 Ethical Guidelines of the Alzheimer Society of Canada  
*John D Fisk, A Dessa Sadovnick, Carole A Cohen, Serge Gauthier, John Dossetor, Astrid Eberhart and Linda LeDuc*
- 249 Platelet Monoamine Oxidase B Activity in "de novo" and L-dopa Treated Parkinsonian Patients and Controls  
*Wilfried Kuhn, Thomas Müller, Anja Gerstner, Regina Winkel and Mario E Goetz*
- 252 Pathological Laughter Following Intravenous Sodium Valproate  
*PC Jacob and R Pratap Chand*
- 254 Seronegative Myasthenia Gravis and Human Immunodeficiency Virus Infection: Response to Intravenous Gamma Globulin and Prednisone  
*James Strong and Douglas W Zochodne*
- ## NEUROLOGICAL PRACTICE
- 257 Canadian Guidelines for Intravenous Thrombolytic Treatment in Acute Stroke: A Consensus Statement of the Canadian Stroke Consortium  
*JW Norris, A Buchan, R Cote, V Hachinski, SJ Phillips, A Shuaib, F Silver, D Simard, P Teal on behalf of the Canadian Stroke Consortium*
- ## SUPPLEMENT 3
- S1 A New Advance in the Treatment of Epilepsy: A Focus on Topiramate

**34th CANADIAN  
CONGRESS OF  
NEUROLOGICAL  
SCIENCES**

June 15 - 19, 1999

Edmonton, Alberta



With Epival, it can be.



Epival has been proven effective in primary generalized epilepsy,<sup>1,3</sup> as well as in partial seizures that secondarily generalize.<sup>4,5\*</sup> Just as importantly, Epival has been associated with little effect on learning and cognition,<sup>6</sup> and is generally well tolerated in properly screened patients.<sup>7†</sup>



Because as your epilepsy patients can confirm, there's more to anticonvulsant therapy than seizure control.

# THIS SHOULD BE THE ONLY INDICATION THEY HAVE EPILEPSY.

Epival<sup>®</sup>  
(divalproex sodium)

Epival<sup>®</sup>  
(divalproex sodium)

BACK IN CONTROL.

# Epival<sup>®</sup>

(divalproex sodium)

HELPS PUT PATIENTS BACK IN CONTROL.

ABBOTT LABORATORIES LIMITED  
PHARMACEUTICALS DIVISION

ABBOTT LABORATORIES  
PHARMACEUTICAL PRODUCTS DIVISION

## HELPS PUT PATIENTS BACK IN CONTROL.

Epival is used as sole or adjunctive therapy in the treatment of simple or complex absence seizures, including petit mal and is useful in primary generalized seizures. Epival may also be used adjunctively in patients with multiple seizure types which include either absence or tonic-clonic seizures. Caution is advised in children < 10 years on multiple AEDs.

For use as sole or adjunctive therapy in the treatment of simple or complex absence seizures, including petit mal and is useful in primary generalized seizures with tonic-clonic manifestations. Epival may also be used adjunctively in patients with multiple seizure types which include either absence or tonic-clonic seizures. Frequent monitoring of hepatic function and blood coagulation is advised.

Product Monograph available on request.



ABBOTT LABORATORIES LIMITED  
PHARMACEUTICAL PRODUCTS DIVISION

© Abbott Laboratories, Limited, Saint-Laurent, Québec H4S 1Z1

For brief prescribing information, see pages A48, A49, A52

For use as sole or adjunctive therapy in the treatment of simple or complex absence seizures, including petit mal and is useful in primary generalized seizures with tonic-clonic manifestations. Epival may also be used adjunctively in patients with multiple seizure types which include either absence or tonic-clonic seizures. Frequent monitoring of hepatic function and blood coagulation is advised. Caution is advised in children < 10 years on multiple AEDs.

© Abbott Laboratories, Limited, Saint-Laurent, Québec H4S 1Z1

Product Monograph available on request.



## Supplement

# A New Advance in the Treatment of Epilepsy: A Focus on Topiramate

Chairman: Joseph Bruni  
Saskatoon, June 1997

The Satellite Symposium "A New Advance in the Treatment of Epilepsy: A Focus on Topiramate" was held during the 32nd Canadian Congress of Neurological Sciences in Saskatoon on June 25, 1997. The symposium consisted of five separate presentations by experts in the field of epilepsy.

Topiramate: Pharmacokinetics and Pharmacodynamics <i>Jack Schneiderman</i> .....	S3
Efficacy of Topiramate <i>Joseph Bruni</i> .....	S6
Topiramate Use in Pediatric Patients <i>Tracy Glauser</i> .....	S8
Topiramate: Safety and Tolerability <i>Michael Jones</i> .....	S13
Using Topiramate in Patients with Epilepsy: Practical Aspects <i>J.W.A.S. Sander</i> .....	S16

## ACKNOWLEDGEMENTS

*The authors express their gratitude to the following individuals and organizations: Mrs. Lucile Edwards, Secretariat, The Canadian Congress of Neurological Sciences, for her assistance in planning the meeting; Janssen-Ortho Inc. for financial support for the meeting and publication of this symposium; and all the attendees of the symposium for their interest and active participation.*